Keros Therapeutics initiated with an Outperform at Scotiabank

Scotiabank analyst Greg Harrison initiated coverage of Keros Therapeutics with an Outperform rating and $77 price target The company’s next-generation approach to targeting transforming growth factor-beta “de-risks” the pipeline and offers opportunity for improvement, the analyst tells investors in a research note. The firm expects the KER-050 update later this year to be incremental, but says further extended duration of response “could be differentiating.”